MedTrace Logo

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

NCT04513652 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2022-09-28

Study results available
· View outcomes & findings →

Summary

This is a Phase 3, randomized, placebo-controlled, double masked, parallel design study in healthy subjects performed in the US. It is designed to evaluate the safety and anesthetic efficacy of AG-920 Sterile Topical Ophthalmic Solution.

Conditions

  • Anesthesia, Local

Interventions

DRUG

AG-920

AG-920 Sterile Topical Ophthalmic Solution

DRUG

Placebo

Placebo Topical Ophthalmic Solution

Sponsors & Collaborators

  • American Genomics, LLC

    lead INDUSTRY

Principal Investigators

  • Martin Uram, MD · Medical Expert

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-03
Primary Completion
2020-09-30
Completion
2020-12-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04513652 on ClinicalTrials.gov